AMARIN CORPORATION PLC

Consensus Amarin Corporation plc

Stocks

AMRN

US0231114044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 31/07/2026 BST			5-day change	1st Jan Change
14.26 ^USD	+0.21%		+5.24%	+2.19%

07-29	Amarin Corporation plc, Q2 2026 Earnings Call, Jul 29, 2026
07-29	European Equities Traded in US as ADRs Ease in Wednesday Trading	MT

Evolution of the Average Target: Amarin Corporation plc

Evolution of the Target Price: Amarin Corporation plc

Changes in Analyst Recommendations: Amarin Corporation plc

39dde16e17a71910f.8DcGTsbLGUR1IQRKYkqSm7DbEpfUyyfubALORTSjFFQ.w1Z_foCITzM6UGN4CwjAyPu5faGQrEvbAlu3D3jQWBuSeT4j95t6CEVWYw~8c0357c2f7b7791dcc6790e483a09640

Analysts' recommendations: Amarin Corporation plc

27/10/25	Amarin issues statement supporting FDA's action to revise labeling for fenofibrate drugs reinforcing a lack of cardiovascular benefit	RE
25/06/25	RBC Ups Recordati's Price Target on Cardiovascular Drug European Licensing Deal	MT
25/10/23	Jefferies Downgrades Amarin to Hold From Buy, Cuts Price Target to $1 From $3	MT
19/07/23	Northland Adjusts Price Target on Amarin to $1.25 From $2, Maintains Market Perform Rating	MT
06/01/23	Jefferies Upgrades Amarin to Buy From Hold, Adjusts Price Target to $3 From $1.30	MT
19/10/22	SVB Securities Adjusts Amarin's Price Target to $2 From $3, Maintains Market Perform Rating	MT
06/05/22	JPMorgan Downgrades Amarin to Underweight From Neutral	MT
05/05/22	HC Wainwright Lowers Amarin to Neutral From Buy, Price Target to $3 From $10	MT
05/05/22	SVB Leerink Downgrades Amarin to Market Perform From Outperform, Adjusts Price Target to $3 From $10	MT
05/05/22	Northland Downgrades Amarin to Market Perform From Outperform, Adjusts Price Target to $2 From $9	MT
16/02/22	SVB Leerink Adjusts Amarin's Price Target to $10 from $11, Maintains Outperform Rating	MT
31/01/22	SVB Leerink Adjusts Amarin's Price Target to $11 from $12, Keeps Outperform Rating	MT
12/05/21	AMARIN : Goldman Sachs Downgrades Amarin to Sell From Neutral, Adjusts Price Target to $5 From $6	MT
01/02/21	AMARIN : SVB Leerink Adjusts Price Target on Amarin to $16 From $12, Maintains Outperform Rating	MT
23/12/20	AMARIN : Goldman Sachs Adjusts Amarin's Price Target to $6 From $8, Maintains Neutral Rating	MT
07/12/20	AMARIN : Citigroup Adjusts Amarin's Price Target to $7 from $12, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AMARIN CORPORATION PLC			-	-	-15.67%
	WUXI APPTEC CO., LTD.					+19.92%
	ARGENX SE					+20.09%
	BIONTECH SE					+31.37%
	INSMED INCORPORATED					+93.3%
	WUXI BIOLOGICS (CAYMAN) INC.					+24.59%
	GENMAB A/S					+29.72%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+17.9%
	EXELIXIS, INC.					-6.97%
	PHARMAESSENTIA CORPORATION					+4.71%
	Average					+21.90%
	Weighted average by Cap.					+26.50%

See all sector consensus

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

SELL

Number of Analysts

1

Last Close Price

14.23USD

Average target price

12.00USD

Spread / Average Target

-15.67%

High Price Target

12.00USD

Spread / Highest target

-15.67%

Low Price Target

12.00USD

Spread / Lowest Target

-15.67%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Jefferies & Co.
Northland Securities
SVB Securities LLC
JPMorgan Chase
SVB Leerink
HC Wainwright
Goldman Sachs

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

SELL

Number of Analysts

1

Last Close Price

14.23USD

Average target price

12.00USD

Spread / Average Target

-15.67%

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Stock Market
Stocks
AMRN Stock
Consensus Amarin Corporation plc

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Unlock them now!